Early effects of human papillomavirus vaccination in Belgium
Authors & affiliation
Mireille Merckx, Davy Vanden Broeck, Ina Benoy, Christophe Depuydt, Steven Weyers, Marc Arbyn
Abstract
Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.
Publication date:
2015
Staff members:
Link to publication
Attachments
CEJejcp061917.pdf (restricted)Related publications
Griffins Manguro, Abednego M. Musau, Daniel K. Were, Soud Tengah, Brian Wakhutu, Jason Reed, Marya Plotkin, Stanley Lüchters, Peter Gichangi, Marleen Temmerman
2020 Cohort profile : the Kaloleni/Rabai community health and demographic surveillance systemAnthony K Ngugi, Rachael Odhiambo, Felix Agoi, Amyn Lakhani, James Orwa, Jerim Obure, David Mang’ong’o, Stanley Lüchters, Catherine Munywoki, Anisa Omar, Marleen Temmerman
2016 Surveillance of effects of HPV vaccination in BelgiumMarc Arbyn, Davy Vanden Broeck, Ina Benoy, Johannes Bogers, Christophe Depuydt, Marleen Praet, Philippe De Sutter, Anne Hoorens, Esther Hauben, Willy Poppe, Marc Van Ranst, Philippe Delvenne, Stephanie Gofflot, Michel Pétein, Frans Engelen, Alain Vanneste, Lode Op De Beeck, Pierre Van Damme, Marleen Temmerman, Steven Weyers